<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="6801">Metformin</z:chebi> use has been associated with decreased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>However, the effects of <z:chebi fb="0" ids="6801">metformin</z:chebi> on the development of colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath>, the precursors of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, are not defined </plain></SENT>
<SENT sid="2" pm="."><plain>AIMS: This study aimed to evaluate the potential effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> on the incidence of colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> in diabetic patients with previous <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking <z:chebi fb="0" ids="6801">metformin</z:chebi> and 126 patients not taking <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Patient demographics, clinical characteristics, and colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> incidence rate were analysed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: After a median follow-up of 58 months, a total of 33 patients (28.9%) exhibited adenomatous colorectal <z:mpath ids='MPATH_491'>polyps</z:mpath> among the 114 patients who used <z:chebi fb="0" ids="6801">metformin</z:chebi>, compared with 58 (46.0%) patients with colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> among the 126 patients who did not use <z:chebi fb="0" ids="6801">metformin</z:chebi> (odds ratio = 0.48, 95% confidence interval = 0.280-0.816, P = 0.008) </plain></SENT>
<SENT sid="6" pm="."><plain>After adjustment for clinically relevant factors, <z:chebi fb="0" ids="6801">metformin</z:chebi> use was found to be associated with a decreased incidence of colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> (odds ratio = 0.27, 95% confidence interval = 0.100-0.758, P = 0.012) in diabetic patients with previous <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> use in diabetic patients with previous <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is associated with a lower risk of colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> </plain></SENT>
</text></document>